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1.3.  Design1.  Summary  of  Focal  Article
1.1.  Focal  Article
Wang F, Sun L, Zhang XZ, Jia J, Liu Z, Huang XY, Yu SY, Zuo
LJ, Cao CJ, Wang XM,  Zhang W.  Effect and Potential Mech-
anism of Electroacupuncture Add-On Treatment in Patients
with Parkinson’s Disease. Evid Based Complement Alternat
Med. 2015;2015:692795. doi: 10.1155/2015/692795. Epub 2015
Aug 131
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The authors aimed to evaluate the effectiveness of elec-
troacupuncture (EA) and explore its mechanisms in Parkin-
son’s disease (PD) patients when used as an adjunctive therapy
to conventional drugs.yung Hee University Korean Medicine Hospital, Hoegi-dong,
This study was a randomized, controlled (EA + drug vs. drug
alone), assessor-blind, single-center, pilot trial.

















































o. Leem/Effectiveness of acupuncture in Parkinson’s Disease 
.4.  Setting
D patients were recruited from May 2011 to May 2012 in the
epartment of Geriatrics and Neurology of Beijing Tiantan
ospital at Capital University.
.5.  Participants
ifty PD patients using a stable dosage of anti-PD medication
or at least two months without adverse effects were recruited.
atients were diagnosed by a neurologist according to the UK
arkinson’s Disease Society Brain Bank criteria2. Patients with
arkinson plus syndrome or secondary Parkinson syndrome
ere not included.
Thirty patients were allocated to the treatment group (EA
 drug). Twenty patients were allocated to the control group
drug only). During the clinical trial period, patients were not
llowed to change their medication. Two patients dropped out
ue to PD medication changes.
.6.  Intervention
eedles 0.25 mm in diameter and 40 mm in length (Huatuo)
ere inserted into the following 6 acupoints based on previ-
us studies: 3,4 bilateral GB20 (Pungji) and LI4 (Hapgok), and
entral GV16 (Pungbu) and GV14 (Daechu). The needles were
timulated using the following parameters for 30 minutes: 9 V,
 A, 9 W,  and 100 Hz (KWD-808-II; Yingdi, China). One acupunc-
ure treatment course is composed of 10 sessions that occur
very 3 days. Two treatment courses, equating to a total of
0 sessions of acupuncture treatment, were performed over
 months. Participants who skipped more  than 2 sessions of
reatment were eliminated from the trial.
.7.  Main  Outcome  Measures
.7.1.  Assessment  schedule
ssessments were performed 12 hours after the latest intake
f PD medication. Treatment group patients were assessed
fter the completion of the entire EA treatment course. Con-
rol group patients were assessed 2 months after the baseline
ssessment date.
.7.2.  Motor  symptoms  and  motor  complications
he following items from the Uniﬁed Parkinson’s Disease Rat-
ng Scale (UPDRS) III were used: total score, items 20 and
1 (tremor), item 22 (rigidity), and items 23-26 (bradykine-
ia). Hoehn–Yahr (H-Y) stage ratings were used to indicate the
everity of PD and the UPDRS IV was used to assess motor
omplications.
.7.3.  Non-motor  symptoms
on-motor symptoms were assessed using the following
ests: Nonmotor Symptoms Quest (NMSQ), including the
ontreal Cognitive Assessment (MoCA); Mini-Mental State
xamination (MMSE) for the assessment of cognitive function;
amilton
Depression Scale (HAMD) 24-item test for the assessment
f depression, Hamilton Anxiety Scale (HAMA) 14–item test for333
the assessment of anxiety, and Pittsburgh Sleep Quality Index
(PSQI) for the assessment of sleep quality. 1
1.7.4.  Activity  of  Daily  Life  (ADL)  and  Quality  of  Life
(QOL)
The UPDRS II and the ADL scale were used to assess ADL. QOL
was evaluated using the Parkinson’s Disease Quality of Life
Questionnaire (PDQ) 39 item test.
1.7.5.  Neuroinﬂammatory  factors  and  Neurotransmitters
in Serum
The following neuroinﬂammatory factors were measured:
nitric oxide (NO), tumor necrosis factor- (TNF-),  interleukin-
1 (IL-1), and prostaglandin (PG) E2.
The following neurotransmitters were measured:
dopamine (DA), acetylcholine (Ach), norepinephrine (NE),
and 5-hydroxytryptamine (5-HT).
1.8.  Main  Results
1.8.1.  Comparison  between  treatment  and  control  groups
The UPDRS III score changes were signiﬁcantly different before
and after treatment. The change in the UPDRS III score was
4.9 ± 4.8 in the treatment group and 2.3 ± 3.0 in the control
group. The change in the PSQI was 1.0 (0.0-2.0) in the treat-
ment group, which was signiﬁcant, while it was 0 in the control
group. However, the H-Y stage, HAMD, HAMA, MMSE, and
MoCA were not different between the two groups. The only
biomarker that was signiﬁcantly different following the treat-
ment was the NO level (treatment group, 53.18 [6.42-64.51];
control group, 80.49 [62.15-107.57]).
1.8.2.  Within-group  comparisons  (before  vs.  after
comparison  in  the  treatment  group)
The motor symptoms evaluated using the UPDRS III score
(25.6 ± 2.8 to 20.6 ± 2.7), and the tremor (4.9 ± 4.4 to 3.4 ± 3.9),
rigidity (4.6 ± 3.4 to 3.6 ± 3.2), and bradykinesia (9.0 ± 6.3 to
7.4 ± 5.9) sub-items were signiﬁcantly improved following
treatment. Subgroup analysis revealed that the UPDRS III
scores were decreased in patients with rigidity-bradykinesia
type or mixed type PD, but not in those with tremor type PD.
UPDRS III scores of patients with mild severity group were
signiﬁcantly improved (20.2 ± 2.6 to 14.7 ± 2.0), whereas those
with moderate severity group did not show the signiﬁcant
improvement (33.5 ± 3.9 to 29.1 ± 4.1). The non-motor symp-
toms assessed using the PSQI and HAMD were improved, but
no improvements were seen in other variables.
1.9.  Authors’  conclusion:
The motor symptoms of PD were signiﬁcantly decreased by
the addition of EA to standard treatment. These improve-
ments were measured using the UPDRS III score and were
especially evident in patients with mixed type or rigidity-
bradykinesia type PD and in those with mild PD symptoms. EA
treatment also improved the quality of sleep and depression in
PD patients. Elevated NO levels may be a possible mechanism
underlying the effects of EA.
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2.  Comment/Critique
The focal article indicates that EA improves motor symp-
toms, as assessed by the UPDRS III, and a non-motor symptom
(quality of sleep), as measured by the PSQI. Several previ-
ous reports on the use of acupuncture did not indicate motor
symptom improvement following this treatment. 5,6 However,
positive reports on the use of acupuncture for PD treatment are
increasing. Cho et al., 3 reported that 16 sessions of acupunc-
ture or bee venom treatment improve the UPDRS III score in
treated patients in comparison to patients in the no treatment
control group in a 3-arm pilot randomized controlled trial. In
another prospective open-label study, 11 participants under-
went 12 consecutive weeks of conventional treatment and 12
weeks of conventional treatment combined with acupuncture
and bee venom treatment. UPDRS II and III scores were signif-
icantly improved in the combined treatment phase compared
to the conventional treatment phase. 7 In another randomized
study, 36 sessions of adjunctive acupuncture therapy com-
bined with western medication over 18 weeks led to a higher
UPDRS total score improvement ratio (55% vs. 15%, p = 0.019)
compared to medication-only group. 8 Acupuncture is also
shown to have long-term effects. Patients in an L-dopa-only
group (control group) and those in an L-dopa and acupunc-
ture combination group (treatment group) were followed for
60 months. Patients in the treatment group received acupunc-
ture treatment 2 to 4 times a month. Over the course of 5 years,
UPDRS III scores worsened by 18.2 ± 9.8 points in the control
group, but the only worsened by 11.9 ± 6.8 points in the treat-
ment group (p = 0.043). 9 A recent meta-analysis of combined
traditional east Asian medicine therapies, including acupunc-
ture, moxibustion, herbal medicine, patent medicine, manual
therapy, and qigong indicated that these treatments improved
the UPDRS III score by 2.45 points [95% conﬁdence interval (CI)
(2.03 to 2.86)] and diminished 38% of the side effects associated
with conventional drugs [risk ratio, 0.62 95% CI (0.40-0.96)]. 10
The original focal article contains a considerable amount of
discussion regarding the mechanisms underlying the effects
of acupuncture in PD treatment. There are several articles dis-
cussing these mechanisms. An original article points to GABA
activity in the substantia nigra as a factor mediating changes
in motor symptoms, suggests NE and 5-HT decreases as fac-
tors underlying changes in depression, and DA changes as
factors mediating changes in the incidence of sleep disorders.
1 However, in the focal article, there were no signiﬁcant dif-
ferences in these markers between the treatment and control
groups, except for changes in serum NO levels. There were
only within-group before and after differences in several of
the neuroinﬂammatory factors and neurotransmitters. The
authors thus failed to ﬁnd a possible mechanism underlying
the effects of EA treatment in patients with PD in this trial.
What is more  interesting in this article is that it identiﬁes
potential responders to EA treatment in PD. In this article,
the mild severity group (H-Y stage 1 to 2) showed signiﬁcant
improvement after treatment. This effect was not observed in
the moderate severity group (H-Y stage 2.5 to 3). This indicates
that early EA treatment in PD may be helpful in alleviating
motor symptoms. In a previous study, H-Y stage and age were
predictive of the effects of integrated Chinese and westernIntegr Med Res ( 2 0 1 6 ) 332–335
therapy as evaluated using the UPDRS III score. 11 The authors
thus hypothesize that the severity of PD is a determinant of
EA treatment response. Another subgroup analysis revealed
that participants with tremor type PD did not improve fol-
lowing treatment. However those with rigidity–bradykinesia
type or mixed type PD showed improvements after EA treat-
ment. This indicates that the EA effect may not be the same in
the different subtypes of the disease. These hypotheses may
be supported by several observational studies. Observational
studies are appropriate when designing feasible clinical trial
protocols with large sample sizes. 12 There are insufﬁcient
resources, such as funding and manpower, for acupuncture
research. As a result, there will not be any well-designed
research exploring the response to acupuncture in the foresee-
able future. However, knowing the response to acupuncture
is a very important factor in designing appropriate clinical
trial protocols and is a critical factor in the success of such
clinical trials. A retrospective chart review or a retrospec-
tive cohort study using national health insurance data will
be helpful in identifying patient who will improve following
acupuncture treatment. Thus, the most valuable discovery of
this focal article is the potential identiﬁcation of responders
to this treatment. I recommend that the authors deﬁne the
responder and the non-responder group and compare base-
line characteristics, severity, symptom subtype, and the levels
of neuroinﬂammatory factors and neurotransmitters between
these groups despite the small sample size.
This article indicates that acupuncture improves motor
symptoms and quality of sleep in patients with PD. Lower
NO levels in the treatment group indicate that acupuncture
suppresses neuroinﬂammation, a hypothesis that should be
tested by further research. The most interesting aspect of
the focal article is the potential identiﬁcation of responders
to acupuncture treatment. At this point, more  observational
studies are needed, and not clinical trials, to study the char-
acteristics of acupuncture treatment responders with PD.
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